3 completed. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
Follow ReCode Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance RCT1100 - Primary Ciliary Dyskinesia (PCD) | Phase 1 | Completed | ReCode Therapeutics | 14 | 2024-10-22 | 2026-04-30 |
| A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults With PCD RCT1100 - Primary Ciliary Dyskinesia | Phase 1 | Completed | ReCode Therapeutics | 7 | 2024-09-20 | 2025-10-08 |
| Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects RCT1100 - Primary Ciliary Dyskinesia | Phase 1 | Completed | ReCode Therapeutics | 9 | 2023-02-18 | 2025-04-29 |
Ciliary Motility Disorders (3) · Kartagener Syndrome (3)
United Kingdom (2) · United States (2) · Australia (1) · Denmark (1) · Germany (1) · New Zealand (1)
John Matthews, MBBS, MCRP, PhD (3) · Heymut Omran, MD (1) · Kim G Nielsen, Dr Med Sci (1) · Michael Loebinger, MD (1)